| Yang, Shujun |
MRG002-006, NCT04839510: A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer |
|
|
| Recruiting | 2 | 58 | RoW | MRG002 | Shanghai Miracogen Inc. | Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 06/22 | 09/22 | | |
NCT04956926: Clinical Study of JS201 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 244 | RoW | JS201 | Shanghai Junshi Bioscience Co., Ltd. | Patients With Advanced Malignant Tumors | 07/23 | 07/23 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05024539: Real-World Effectiveness of Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | nonintervention | Shujun Yang, Henan Cancer Hospital | Hepatocellular Carcinoma | 11/22 | 12/22 | | |
NCT05023720: Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 300 | RoW | nonintervention | Henan Cancer Hospital | Metastatic Colorectal Cancer | 12/22 | 12/22 | | |
| Qin, Yanru |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Enrolling by invitation | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT05254665: A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 2 | 110 | RoW | Docetaxel Polymeric Micelles for Injection | Jiangsu Simcere Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 03/24 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations |
|
|
| Recruiting | 2 | 200 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT06492317: RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 20 | RoW | Disitamab Vedotin, RC48, Cadonilimab, AK104 | The First Affiliated Hospital of Zhengzhou University | HER2-positive Gastric Cancer | 07/26 | 07/27 | | |
NCT04838964: A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 80 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 10/24 | 11/24 | | |
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) |
|
|
| Recruiting | 2 | 110 | RoW | Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma | 12/26 | 12/27 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
| Recruiting | 1/2 | 222 | RoW | SHR-1701, Famitinib | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 10/23 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
NCT05315167: A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 267 | RoW | PRJ1-3024 | Zhuhai Yufan Biotechnologies Co., Ltd | Advanced Solid Tumor, Advanced Solid Malignancies | 05/27 | 11/27 | | |
| Completed | 1 | 134 | RoW | CAR-CLDN18.2 T-Cells, Chimeric Antigen Receptor T Cells Targeting Claudin18.2, PD-1 Monoclonal Antibody, Toripalimab, Chemotherapy | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Solid Tumor | 03/21 | 01/24 | | |
NCT05155189: A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 44 | RoW | C-CAR031, Lenvatinib, PD-1(L1) monoclonal antibody | Zhejiang University | Hepatocellular Carcinoma | 05/26 | 05/41 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
| Li, Jiang-tao |
NCT03314532: The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 230 | RoW | TILA-TACE | Second Affiliated Hospital, School of Medicine, Zhejiang University | Surgical Resection, HCC | 12/20 | 12/22 | | |
NCT04078230: Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 168 | US, RoW | Extend LymphAdenectomy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Intrahepatic Cholangiocarcinoma | 12/27 | 12/27 | | |
| Dong, Xiaorong |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06280196: A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC |
|
|
| Recruiting | 3 | 676 | RoW | BAT3306, Pembrolizumab Injection, EU-Keytruda®, US-Keytruda®, Pemetrexed, Pemetrexed Fresenius Kabi, Carboplatin, Carboplatin Kabi | Bio-Thera Solutions | Carcinoma, Non-Small-Cell Lung | 07/27 | 10/28 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC |
|
|
| Recruiting | 2 | 63 | RoW | GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy | Fudan University | NSCLC Stage IV | 08/22 | 08/23 | | |
NCT05738317: Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment |
|
|
| Recruiting | 2 | 45 | RoW | Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel | Xiaorong Dong | Non-small Cell Lung Cancer | 06/23 | 12/24 | | |
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib |
|
|
| Recruiting | 2 | 54 | RoW | ABSK043 in combination with Firmonertinib | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer With EGFR Mutation | 12/27 | 06/28 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI |
|
|
| Recruiting | 2 | 202 | RoW | EGFR-TK Inhibitor, Stereotactic radiotherapy | Fudan University | Brain Metastases, Non-small Cell Lung Cancer | 08/28 | 08/29 | | |
| Recruiting | 1/2 | 310 | RoW | ICP-723 | Beijing InnoCare Pharma Tech Co., Ltd. | Solid Tumors | 06/25 | 02/28 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT06144671: GT201 Injection For The Treatment Of Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 18 | RoW | GT201 | Grit Biotechnology | Solid Tumor, Adult | 09/26 | 09/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
NCT05367778: Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 176 | RoW | HS-10370 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT04489862: αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors |
|
|
| Recruiting | 1 | 10 | RoW | αPD1-MSLN-CAR T cells | Wuhan Union Hospital, China, Shanghai Cell Therapy Group Co.,Ltd | Non-small-cell Lung Cancer, Mesothelioma | 06/22 | 12/22 | | |
NCT05025358: A Study of LP-118 in Patients with Advanced Tumors |
|
|
| Active, not recruiting | 1 | 96 | RoW | LP-118 tablet, NWP-4-76 | Guangzhou Lupeng Pharmaceutical Company LTD. | Solid Tumor, Lymphoma, Non-Hodgkin | 01/25 | 12/25 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients with Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/25 | 12/25 | | |
NCT05430386: Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1 | 174 | RoW | HS-10241, Almonertinib | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Non Small Cell Lung Cancer | 12/23 | 12/23 | | |
| Recruiting | 1 | 31 | US, RoW | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect | Adlai Nortye Biopharma Co., Ltd. | Advanced Solid Tumor, Advanced Lymphoma | 08/25 | 12/25 | | |
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 164 | US, RoW | ABSK112, EGFR Exon20 inhibitor | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer | 03/27 | 03/28 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05737589: Circulating Tumor DNA and T Cell Repertoire Predict Radiotherapeutic Outcomes in NSCLC Patients With Brain Metastasis |
|
|
| Not yet recruiting | N/A | 50 | RoW | Whole-brain radiotherapy, Stereotactic radiotherapy | Xiaorong Dong | Carcinoma, Non-Small-Cell Lung, Brain Metastases | 02/24 | 10/24 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
| Huang, Pintong |
NCT04931511: Comparison Between Subacromial Ultrasound Guided and Systemic Steroid Injection for Frozen Shoulder |
|
|
| Terminated | 4 | 20 | RoW | Compound betamethasone Injection(Gluteal muscle injection), corticosteroid, Compound betamethasone Injection(Subacromial Ultrasound Guided injection), Physical therapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Frozen Shoulder, Shoulder Pain, Bursitis | 09/22 | 09/22 | | |
| Active, not recruiting | N/A | 260 | RoW | imaging, in-vitro | Second Affiliated Hospital, School of Medicine, Zhejiang University, Beijing Friendship Hospital | PCA, Breast Cancer | 05/20 | 12/21 | | |
| Recruiting | N/A | 400 | Europe, Japan, US, RoW | Ultrasound application | Tokyo Medical University | Nonalcoholic Steatohepatitis, Ultrasound, Elastography | 07/22 | 07/22 | | |
NCT04544657: Artificial Intelligence Based Comprehensive Assessment System of Carotid Plaque Stability |
|
|
| Recruiting | N/A | 2000 | RoW | no intervention | Second Affiliated Hospital, School of Medicine, Zhejiang University | Carotid Atherosclerosis | 12/22 | 12/22 | | |
NCT05849909: Evaluation of the Vulnerable Carotid Atherosclerotic Plaque: A Clinical Multicenter Study |
|
|
| Recruiting | N/A | 57 | RoW | | huang pintong, Second Affiliated Hospital, School of Medicine, Zhejiang University | Ultrasound | 04/23 | 04/24 | | |
NCT06172270: Sub-regional Tumor Segmentation Based on CEUS Perfusion Characteristics: Enhancing Breast Tumor Diagnosis |
|
|
| Completed | N/A | 339 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Tumor | 01/25 | 01/25 | | |
| Recruiting | N/A | 2000 | RoW | Endocrine therapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer, Ultrasound, Elastography, Pathology, Radiomics | 12/23 | 12/28 | | |
NCT04920214: Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC |
|
|
| Recruiting | N/A | 500 | RoW | SonoVue | Second Affiliated Hospital, School of Medicine, Zhejiang University, Tianjin Third Central Hospital, Sichuan Provincial People's Hospital, Fujian Cancer Hospital, Shandong Jining No.1 People's Hospital, General Hospital of Ningxia Medical University, Beijing Hospital, Red Cross Hospital, Hangzhou, China, Zhejiang Cancer Hospital, Shengjing Hospital | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
NCT06139250: Development of a High-speed Multimodal Photoacoustic/Ultrasound System for Functional Imaging of the Neonatal Brain |
|
|
| Not yet recruiting | N/A | 140 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Hypoxia-Ischemia, Brain | 01/25 | 01/25 | | |
NCT03808779: A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma. |
|
|
| Recruiting | N/A | 200 | RoW | Radiofrequency Ablation, RFA, Conventional Surgery, Total thyroidectomy/Thyroid lobectomy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Papillary Thyroid Microcarcinoma | 02/24 | 02/24 | | |
NCT06590948: Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS |
|
|
| Recruiting | N/A | 50 | RoW | contrast-enhanced ultrasound | Second Affiliated Hospital, School of Medicine, Zhejiang University | Liver Cancer | 07/25 | 07/26 | | |
HOPE-1, NCT05611359: Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer |
|
|
| Not yet recruiting | N/A | 60 | NA | Thermal Ablation, Thermal Ablation Combined with Chemotherapy, Chemotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Pancreatic Ductal Adenocarcinoma | 12/26 | 12/26 | | |
| Active, not recruiting | N/A | 500 | RoW | SMI, CEUS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Lymphadenopathy, ULTRASOUND | 12/20 | 12/22 | | |
NCT04490746: Identifcation of Biomarkers for Active Pulmonary Tuberculosis |
|
|
| Not yet recruiting | N/A | 100 | RoW | with no intervention, Collect samples | Second Affiliated Hospital, School of Medicine, Zhejiang University | Tuberculosis, Diagnosis | 10/22 | 10/22 | | |
| Lou, Honggang |
NCT05917964: A Food Effect Study of LP-168 Tablets in Healthy Subjects |
|
|
| Completed | 1 | 22 | RoW | LP-168 tablet, NWP-775 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma | 08/23 | 08/23 | | |
| Active, not recruiting | N/A | 51 | RoW | MitraClip procedure | Abbott Medical Devices | Mitral Regurgitation | 05/24 | 05/25 | | |
| Lin, zimei |
| Recruiting | N/A | 2000 | RoW | Endocrine therapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer, Ultrasound, Elastography, Pathology, Radiomics | 12/23 | 12/28 | | |
| Recruiting | N/A | 500 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Ultrasound, Breast Cancer, Pathology | 12/21 | 12/21 | | |
